Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02727777 · ClinicalTrials.gov registry record · Phase 1
Phase II Study of TAK228 in Relapsed Lymphoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02727777: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT02727777 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02727777, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if TAK-228 can help to control relapsed lymphoma. The safety of this drug will also be studied.
Primary Outcome
RA was defined by Lugano Criteria \& based on CT scans obtained at screening \& after completion of every 2 cycles of therapy. Complete Radiographic Response Target Nodes must regress to \<=1.5cm in longest dimension,No extralymphatic sites of disease. PR \>=50% decrease in sum of the product of diameters of up to 6 target measurable nodes and extranodal sites. When a lesion is too small to measure on CT, 5 mmx5mm is assigned. When not visible on CT, assign 0x0 mm. For a node 5mmx5mm use actual
Interventions
- DRUG TAK228
- OTHER Blood Sugar Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2018-07-10 |
| Phase | Phase 1 |
Why NCT02727777 stopped before completion
NCT02727777 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which TAK228 is the first listed.
NCT02727777 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02727777 about?
NCT02727777 is a clinical study titled "Phase II Study of TAK228 in Relapsed Lymphoma". The goal of this clinical research study is to learn if TAK-228 can help to control relapsed lymphoma. The safety of this drug will also be studied.
What is the current status of trial NCT02727777?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2017-03-01. Estimated completion is 2018-07-10.
What interventions are being tested in trial NCT02727777?
The interventions under investigation include: TAK228 (DRUG), Blood Sugar Testing (OTHER).
Who is sponsoring clinical trial NCT02727777?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02727777's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI